Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Adisyn has moved quickly to turn a burst of technical and strategic momentum into cash, lining up a placement of up to 207.4 million shares at 6.75 cents each, which works out to about $14 million before costs. Of that total, 204.4 million shares can be issued under the company’s existing placement capacity, while a further 2.96 million shares for director participation remain subject to shareholder approval. The proposed issue date for the main tranche is 30 April 2026, with the director component to be put to holders on 11 June 2026.

For existing investors, the first point is that this is not a token top-up. It is a meaningful capital raising that will expand the register and reshape the balance sheet. Using ASX’s quoted market capitalisation of $61.72 million and a last price of 7.5 cents, the placement equates to roughly one new share for every four already on issue - a dilution event of about 25%. That is not trivial, but neither is the cheque being written. In small-cap land, a raise of this size usually tells you one of two things: the company is plugging a hole, or institutions think there is enough in the story to fund the next leg properly. Adisyn is clearly pitching the latter.

Institutions are not just turning up - they are cornerstoning it

What lifts this above the run-of-the-mill placement is the identity of the backers. The company says the raising was cornerstoned by Regal Funds Management and Meitav, described as Israel’s largest investment house. That matters because institutional names can act as a form of external validation, particularly for a company whose appeal rests on commercialising advanced materials rather than churning out near-term cash flow. The placement was also led by Sandton Capital Advisory, which will receive a 6% fee, and the director participation totals about $200,000, subject to approval.

The price itself was not especially punitive by small-cap standards. Adisyn says the 6.75 cent issue price represents a 10% discount to the last closing price of 7.0 cents on 21 April 2026 and a 5.78% discount to the 15-day VWAP. In other words, the company raised serious money without having to serve up a bargain-bin special. That suggests the book was supported by investors willing to pay close to market for exposure to the story, which is often a better sign than a deeply discounted rescue mission.

Why the market was prepared to stump up

The timing is no accident. Adisyn has just come off the back of two eye-catching developments. First, it reported a low-temperature graphene deposition result using an industrial atomic layer deposition system, which the company argues is an important step toward semiconductor interconnect applications. Second, it secured exclusive worldwide rights from Tel Aviv University’s commercialisation arm to graphene-based radar absorption technology aimed at defence and drone applications. Together, the pair broaden the investment case from pure lab promise to something closer to a platform story with semiconductor and defence angles.

That does not mean the technology risk has vanished. Far from it. Graphene has a long and colourful history of exciting presentations and limited commercial payoff. What Adisyn has done, though, is give investors two reasons to believe the company may have edged closer to a real addressable market. The semiconductor result goes to manufacturability and process compatibility, while the radar-absorbing materials deal points to a separate, defence-flavoured commercial pathway. When a company can pitch two potentially valuable verticals at once, it tends to get a better hearing from institutions.

What to watch next

The near-term checklist is straightforward. Investors will want to see the main tranche settle and allot on schedule, director participation approved, and - most importantly - evidence that the fresh cash is producing commercial progress rather than just extending the corporate runway. The funds are earmarked for graphene technology programs, business development, working capital and offer costs. That is sensible enough, but broad enough that management now needs to show tangible milestones. A bigger register and a fatter bank account buy time. They do not buy forgiveness forever.

Adisyn has taken a meaningful step in turning a promising materials story into something semiconductor companies might eventually take seriously. The company says it has demonstrated continuous graphene formation on a 1cm x 1cm copper coupon using an industrial atomic layer deposition, or ALD, system, with the process running below the semiconductor sector’s approximate 450C thermal ceiling.

For investors, the key point is not simply that graphene was formed. Graphene has long been touted as a wonder material for chips because of its electrical and thermal properties. The rub has been manufacturing. Semiconductor makers do not like scientific miracles that only work in exotic lab conditions, at heroic temperatures, or with processes that require a factory reset of their production lines. Adisyn’s claim is important because it brings together three things the market wanted to see in the same sentence - graphene, industrial equipment, and semiconductor-compatible temperatures.

That does not make Adisyn a chip industry kingmaker overnight. But it does move the conversation from "interesting science" towards "possibly relevant process technology".

Why copper is the problem child

Adisyn is targeting one of the semiconductor industry’s sore spots: copper interconnects. These are the microscopic wiring systems that link billions of transistors on advanced chips. As geometries shrink, copper becomes more troublesome, with higher resistance, more heat, and more power loss. That in turn threatens performance, efficiency and the industry’s long-running obsession with cramming ever more capability into ever-smaller devices.

If Adisyn’s process can eventually help graphene replace or augment copper in advanced interconnects, the commercial addressable market could be very large. The company is clearly pitching this toward high-value chip segments such as AI processors, GPUs, CPUs, advanced mobile devices and networking hardware. That is the glamour end of semis, where performance gains are prized and bottlenecks matter.

For small-cap investors, that is the allure. Adisyn is not chasing a niche coating application with modest upside. It is trying to insert itself into one of the most strategically important parts of the global semiconductor stack.

The real achievement is process compatibility

What gives this update more weight than the average frontier-tech flourish is the emphasis on industrial compatibility. The work was carried out through subsidiary 2D Generation using a standard industrial ALD system and Adisyn’s patented ALD methodology and precursor chemistry. In plain English, the company is saying its graphene is being made with tools and conditions that resemble the real world of chip fabrication, rather than a one-off bench-top stunt.

Characterisation work using transmission electron microscopy and Raman spectroscopy confirmed continuous graphene layers across the full coupon area, with the cross-section indicating a layer thickness of about 1 nanometre. Continuity matters because interconnect materials cannot afford gaps, inconsistencies or reliability headaches. A discontinuous film may excite scientists, but it will not excite a wafer fab manager.

Chairman Kevin Crofton’s comments were revealing in that regard. He framed the result not as mission accomplished, but as the first step in making graphene relevant from a manufacturing perspective and in addressing one of the sector’s major performance constraints. That is the right tone. The market has seen enough moonshot materials stories to know there is a canyon between proof-of-concept and production adoption.

What comes next, and where the risk still sits

The next stage is less glamorous and probably more important. Adisyn says it will now focus on recipe optimisation, repeatability testing and scaling from coupon-level substrates to wafer-level formats, while also beginning commercial engagement with industry participants.

That is where the hard yards begin. Investors should watch for evidence that the company can reproduce the result consistently, improve film quality, and maintain performance as the substrate size increases. Semiconductor customers care about repeatability, yield, integration and reliability every bit as much as raw material promise. One good result opens the door. A repeatable process is what gets you invited inside.

Commercial discussions with Tier 1 semiconductor groups would also be a useful signal, but they should be treated as a starting pistol rather than a finish line. Collaboration agreements, validation programs and technical engagement sound impressive, yet they do not guarantee revenue or adoption. In deep tech, the time between scientific validation and meaningful commercial returns can be measured in years, not quarters.

The investor takeaway

For Adisyn, this is a credible technical milestone with genuine strategic relevance. It appears to address a long-recognised semiconductor problem using a process that, at least at this early stage, fits more neatly within existing fabrication constraints than many graphene concepts have managed.

The company is still firmly in speculative territory, because scale-up, repeatability and industry qualification remain to be proven. But for investors willing to follow early-stage advanced materials stories, this result strengthens the thesis that Adisyn may have something more substantial than a glossy graphene dream. The company has not yet solved the interconnect dilemma. It has, however, shown that its technology may deserve a place in the conversation.

For long-suffering Memphasys investors, the March quarter offered something rarer than biotech promise - actual customer receipts. The reproductive biotech minnow says quarterly revenue topped $100,000, repeat cartridge orders are now coming through from multiple regions, and more than $1.4 million of multi-year contracted revenue has been secured across Europe and MENA. That marks a notable change in tone for a company that, until recently, was still largely selling the commercial dream of its Felix sperm selection system rather than the product itself.

From science story to sales story

Management is pitching the quarter as proof that its strategic reset late last year is working. The company narrowed its focus to Felix, shifted from a research-led model to commercial execution, set up a commercialisation committee and tightened the cost base. On the numbers presented, that reset is starting to show up where it matters most - revenue, repeat usage and regulatory clearances.

The key point for investors is not just the $106,000 of customer receipts for the quarter, but the nature of those receipts. Memphasys says revenue came from Europe, MENA and Japan, and that repeat cartridge orders are now emerging from existing customers. For a medical device company built around a consumables model, that is the difference between a one-off placement and the early signs of a recurring revenue stream.

Chairman Lindley Edwards put it plainly, saying the company is "no longer a development-stage organisation - it is now generating revenue from commercial sales" of Felix. That is a strong claim, but not an unreasonable one given the first meaningful receipts and the evidence of repeat ordering.

Europe and MENA are doing the heavy lifting

Geographically, Europe looks set to be the main engine room. CE Mark approval and UK CE MDR access open up the company's biggest near-term addressable market, and Italy appears to be the initial beachhead. Management says it is also expanding the broader European pipeline and adding commercial personnel on the ground to improve clinic engagement and conversion.

MENA is shaping up as the second leg of the stool. Clinical use continued in Qatar, repeat cartridge orders were received, and additional orders were secured across the UAE and Iraq. The company is also pushing regulatory and commercial pathways in Egypt and Turkey.

Japan remains smaller but strategically useful, providing another commercial reference point. India is the obvious wildcard. The regulatory submission has been lodged with the CDSCO, and Memphasys says it already has a contracted partner waiting for activation once approval comes through. If that approval lands around mid-2026 as hoped, India could move from PowerPoint opportunity to real contributor.

The real attraction is the consumables model

Investors should remember that Felix is not just about selling a machine into IVF clinics. The larger commercial prize lies in recurring cartridge sales tied to procedure volumes. Memphasys says clinics already using the system are re-ordering cartridges, which suggests Felix is moving beyond evaluation and into workflow integration.

That matters because medical device stories often live or die on utilisation, not installation. A clinic that buys a system but leaves it in the cupboard is worthless. A clinic that incorporates it into routine practice becomes an annuity stream. Memphasys is clearly trying to show the market that it is edging into the second category.

The balance sheet still keeps everyone honest

Before anyone gets carried away, the Appendix 4C is the necessary cold shower. Net operating cash outflow for the quarter was $724,000. Cash at quarter end stood at $420,000, which the company calculates as just 0.58 quarters of funding at the current burn rate. That is thin by any standard.

Yes, the company raised $800,000 in February, with $824,000 of equity proceeds recorded in the quarter before costs. Yes, management says operating cash outflows should reduce as revenue builds, margins improve and some prior-quarter obligations fall away. But the fact remains that Memphasys still needs the commercial ramp to accelerate quickly - or more funding to arrive.

There is also the Peters Investments convertible note to consider. The maturity has been extended to 30 June 2026, with an 8 per cent coupon, giving management a little breathing room. Still, "constructive discussions" are comforting only up to a point. Investors will want clarity on how the next leg of growth is funded, and on what terms.

What matters from here

The company has undoubtedly moved the story forward. Revenue is no longer theoretical, repeat orders matter, and regulatory progress in Europe, Australia and India gives the commercial team more territory to work with. Just as importantly, operating costs have been reduced by $57,000 a month, or 22 per cent, as capital is redirected toward manufacturing and commercialisation.

But the market will not reward Memphasys indefinitely for being merely less speculative than it used to be. The next few quarters need to show rising cartridge usage, more active clinics, and customer receipts that start to make the cash burn look less intimidating.

That is the nub of it. Memphasys has finally produced early evidence that Felix can sell. Now it needs to prove the business can scale before the funding treadmill spins faster than the sales cycle.

Audeara has secured exclusive Australian distribution rights from Shokz Health Global, the healthcare arm of global bone conduction audio group Shokz, in a move that looks more strategic than flashy at first glance. The deal gives Audeara the right to deploy a customised version of ShokzHear’s product for the local market, to be sold as the OpenLearn Small by ShokzHear. For investors, the attraction is not merely another product SKU - it is the prospect of a repeatable, funded pathway into schools, government programs and charitable channels.

The company is pitching the opportunity at a meaningful unmet need. Audeara says up to 600,000 Australian school-aged children experience functional listening challenges, often tied to fluctuating hearing loss. In plain English, that is a very large cohort of children who may struggle to hear clearly in classrooms, particularly noisy ones, during the years when speech clarity and learning outcomes are tightly linked. That gives the deal a social impact angle, but for shareholders the more pertinent issue is whether the company can convert need into volume sales without burning through capital.

Why this partnership matters

The significance of the tie-up lies in the division of labour. ShokzHear is responsible for customisation and manufacturing, while Audeara brings local market knowledge, listening expertise and the route to market in Australia. The product has been adapted using Audeara’s feedback on functionality, size and audio tuning parameters for the local education sector. That means Audeara is not trying to reinvent the hardware wheel - it is leveraging an established global brand while tailoring the device for a specific use case.

That matters because it supports a capital-efficient operating model. Small healthcare and assistive technology companies often face the awkward choice between spending heavily on product development or remaining a distributor with limited differentiation. Audeara is attempting to split the difference: customised product, exclusive local rights, but without the balance-sheet strain that can come with large-scale in-house manufacturing.

The commercial angle - funded channels, lower acquisition cost

Perhaps the most investor-relevant feature of the arrangement is the stated pathway into fully funded state and national government programs, as well as charitable channels. That suggests Audeara is not relying solely on slow, fragmented direct-to-consumer adoption. Instead, it is aiming at institutional procurement, where order sizes can be larger and customer acquisition costs lower if the product wins acceptance.

Management is clearly leaning into that message. Chief executive Dr James Fielding said the agreement would allow Audeara to “deliver at scale through fully funded programs”, while also creating a “scalable and sustainable commercial pathway”. That is the key phrase investors should underline. Plenty of medtech-adjacent minnows can identify a worthy problem; fewer can show a distribution model that does not chew up cash.

The company says it expects to place first orders later this calendar year following initial customer orders. So the deal is strategically important, but it is not yet a revenue floodgate. The next test will be proof of demand, then proof of repeat demand. Investors will want to see whether those initial orders translate into broader procurement wins across schools and support programs.

A targeted product in a difficult niche

Audeara’s pitch is rooted in a real-world problem rather than a consumer gadget story. The company notes that many children, especially those with middle-ear related hearing fluctuation, do not receive consistent support during critical developmental years. It also highlights that some remote communities experience exceptionally high rates of hearing loss, with flow-on effects for education, communication and social connection.

That gives OpenLearn Small a more focused market proposition than generic headphones or hearing accessories. The solution is designed to improve access to speech while maintaining comfort, awareness and ease of use in everyday settings such as classrooms. In investor terms, this is a niche market, but one where the value proposition may be stronger precisely because it addresses a specific pain point.

The fine print investors should note

The agreement runs for an initial two years and can be terminated for cause by either party. So while the exclusivity is meaningful, it is not forever, and execution will matter. Audeara also frames the partnership as part of a broader strategy to expand its hearing health platform through alliances with leading global hardware providers. That hints this may be more than a one-off deal if the model works.

For now, the Shokz arrangement gives Audeara something the market generally likes - a credible partner, a defined commercial use case, and a route to potentially scalable sales. The missing piece, naturally, is evidence of take-up. Until orders start landing, the story remains promising rather than proven. But as strategic small-cap updates go, this one carries more substance than the usual corporate fanfare and fewer whiffs of PowerPoint perfume.

PainChek has secured what looks less like a standard customer contract and more like a new distribution model for the US and Canadian aged care markets. The company has signed a master services agreement with Sabra Health Care REIT, a Nasdaq-listed healthcare property owner with a market value of about US$5 billion, under which Sabra will fund PainChek’s pain assessment platform across as many as 20,000 beds in its network of skilled nursing, long-term care and senior housing facilities.

For investors, that matters because Sabra is not merely another operator signing up for software. It is the landlord, capital provider and introducer. Sabra owns a broad healthcare real estate portfolio across North America and is obliged under the agreement to introduce PainChek to all current and future operators within its portfolio. That shifts the sales pitch from a site-by-site slog to a top-down endorsement by a major asset owner.

PainChek has long talked about scaling internationally after securing regulatory clearances. This deal suggests the company may finally have found a practical way to do that in North America without burning through an outsized sales budget.

The numbers are meaningful, even before full rollout

The headline commercial range is US$55 to US$75 per bed per year. On a fully deployed 20,000-bed base, that implies annualised revenue of about US$1.1 million to US$1.5 million. That is not pocket change for a company of PainChek’s size, particularly given the agreement is structured to reduce friction at the operator level.

The lower end of the pricing range applies to longer-term agreements of two to three years or where customers participate in collaborative research or outcomes publications with PainChek. That detail is important. It tells investors the company is not simply discounting to win volume. It is using pricing to encourage stickier contracts and potentially generate clinical and economic evidence that could support wider adoption.

There is, however, a dose of realism required. The 20,000-bed figure is a target, not day-one revenue. Management says rollout will occur in stages, with local agreements currently being finalised with an initial five operators and a further ten operators in the queue. So while the contract materially improves PainChek’s North American commercial prospects, investors should not assume an overnight revenue flood.

Why the Sabra structure could be the bigger prize

The more interesting angle is the model itself. Sabra is effectively underwriting access to the platform on behalf of its operating partners. That means PainChek can bypass one of healthcare software’s most persistent headaches: getting individual facilities to commit budget, navigate procurement and then justify implementation costs.

If the owner of the real estate is prepared to fund the technology and encourage adoption across its network, the sales cycle should shorten and customer acquisition costs should fall. For a smaller ASX-listed healthtech, that is gold. Scaling offshore often destroys margins before it builds revenue. PainChek is arguing the opposite can happen here.

Management is also clearly signalling that this arrangement is intended as a blueprint for other healthcare REITs and institutional asset owners in North America. That is a bold claim, but not an unreasonable one. The aged care and senior housing sectors are heavily influenced by owners, operators and compliance demands. If PainChek can show improved care processes, better documentation and smoother pain monitoring, other landlords may decide it is cheaper to sponsor adoption than leave operators to muddle through with inconsistent practices.

FDA approval is now being turned into commercial traction

Last year’s FDA clearance was strategically important, but regulatory approval alone does not pay the bills. This Sabra agreement is the first clear sign that PainChek is converting that regulatory milestone into a market entry strategy.

That makes this development more valuable than a plain-vanilla customer win. It gives investors a line of sight on how the company intends to commercialise in a massive but fragmented market. North America is full of healthcare facilities, but it is also full of gatekeepers, procurement layers and painfully slow enterprise sales cycles. PainChek appears to be attacking that complexity through the owners of the assets rather than waiting for every operator to make an individual decision.

What investors should watch next

The next test is execution. Investors will want evidence that the initial operator cohort converts into live deployments, that utilisation follows, and that the queue of additional operators turns into contracted beds rather than polite expressions of interest. They will also want to know where within the US$55 to US$75 range most deals settle, because that will shape the economics of the rollout.

Attention should also turn to whether this arrangement helps PainChek win similar agreements with other North American REITs. That is where the real leverage sits. One landlord-backed deal is promising. Two or three would begin to look like a repeatable market entry channel.

For now, the Sabra deal looks like a genuine commercial inflection point. It offers credible revenue potential, validation from a sizeable North American healthcare property owner, and a capital-light route to expansion that many small healthtechs can only dream about. PainChek still has to prove rollout velocity and conversion, but this is the sort of agreement that gives investors permission to believe the North American story may be moving from theory to practice.